サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1339169

子宮筋腫治療市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、薬剤タイプ別、エンドユース別、地域別、セグメント別予測、2023-2032年

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, & Segment Forecasts, 2023-2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
子宮筋腫治療市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、薬剤タイプ別、エンドユース別、地域別、セグメント別予測、2023-2032年
出版日: 2023年07月23日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の子宮筋腫治療市場規模は2032年までに108億3,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

子宮筋腫（UF）は、生殖年齢の女性に影響を及ぼす一般的な疾患で、月経多量出血は最も一般的な症状の1つです。GnRH拮抗薬や黄体ホルモン放出IUDなどの新規薬剤の開発により、子宮筋腫を持つ女性により効果的な治療選択肢が提供されています。これらの要因は、認知度や診断の増加とともに、市場の成長を促進しています。

IntechOpen社の分析によると、月経過多の出血はUFで最も一般的な症状であり、毎年140万人近くの女性が罹患しています。さらに、女性の約60％が身体的活動低下や生活の質の低下といった症状を訴えています。

子宮筋腫に対するより効果的で安全な治療法に対する需要は高まっており、この分野における研究開発の原動力となっています。研究活動への資金提供の増加に伴い、より先進的で革新的な治療法の開発が期待され、市場の成長をさらに後押しするものと思われます。さらに、個別化医療や精密治療の開拓も、個々の患者により的を絞った効果的な治療選択肢を提供する可能性があるため、市場の成長を促進すると予想されます。

最近、女性健康研究協会（SWHR）が「2021年ステファニー・タブス・ジョーンズ子宮筋腫研究開発法（Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021）」を支持し再提案したことで、子宮筋腫の研究に資金を提供し支援することになり、新規治療法の開発が促進されることが期待されます。さらに、子宮筋腫に伴う大量出血の治療薬として、マイフェンブリーなど複数のGnRH拮抗薬が最近承認されたことも、市場の成長を後押しすると思われます。

子宮筋腫治療市場レポートハイライト

GnRH拮抗薬セグメントは、その高い有効性と効果的な治療オプションにより、より速い成長が予想されます。

粘膜下子宮筋腫の市場が最も大きなシェアを占めています。これは主に、その高い有病率と重症度によるものです。アジア女性に多い

薬剤や他の併用療法を容易に入手できることから、小売薬局セグメントが大きなシェアを獲得すると予想される

北米は、米国における有病率の高さ、医療施設の充実、弊害に対する個人の意識の高さなどから、より大きな成長が見込まれます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の子宮筋腫治療市場に関する洞察

  • 子宮筋腫治療市場- 最終用途のスナップショット
  • 子宮筋腫治療市場力学
    • 促進要因と機会
      • 子宮筋腫患者の人口ベースの増加
      • 子宮筋腫の診断と治療に関する意識の向上への取り組み
    • 抑制要因と課題
      • 厳格な規制の枠組み
  • PESTEL分析
  • 子宮筋腫治療市場の最終使用動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の子宮筋腫治療市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • 性腺刺激ホルモン放出ホルモン（GnRH）アゴニスト
  • 性腺刺激ホルモン放出ホルモン（GnRH）アンタゴニスト
  • プロゲスチン放出子宮内避妊具（IUD）と避妊薬
  • 非ホルモン薬
  • その他

第6章 世界の子宮筋腫治療市場、薬剤の種類別

  • 主な調査結果
  • イントロダクション
  • 漿膜下筋腫
  • 壁内筋腫
  • 粘膜下筋腫
  • 有茎性筋腫

第7章 世界の子宮筋腫治療市場、最終用途別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第8章 世界の子宮筋腫治療市場、地域別

  • 主な調査結果
  • イントロダクション
    • 子宮筋腫治療市場評価、地域別、2019-2032年
  • 子宮筋腫治療市場-北米
    • 北米：子宮筋腫治療市場、薬剤クラス別、2019-2032年
    • 北米：子宮筋腫治療市場、最終用途別、2019～2032年
    • 北米：子宮筋腫治療市場、薬剤タイプ別、2019～2032年
    • 子宮筋腫治療市場-米国
    • 子宮筋腫治療市場- カナダ
  • 子宮筋腫治療市場- 欧州
    • 欧州：子宮筋腫治療市場、薬剤クラス別、2019～2032年
    • 欧州：子宮筋腫治療市場、最終用途別、2019～2032年
    • 欧州：子宮筋腫治療市場、薬剤タイプ別、2019～2032年
    • 子宮筋腫治療市場- 英国
    • 子宮筋腫治療市場- フランス
    • 子宮筋腫治療市場- ドイツ
    • 子宮筋腫治療市場- イタリア
    • 子宮筋腫治療市場- スペイン
    • 子宮筋腫治療市場- オランダ
    • 子宮筋腫治療市場- ロシア
  • 子宮筋腫治療市場- アジア太平洋
    • アジア太平洋：子宮筋腫治療市場、薬剤クラス別、2019～2032年
    • アジア太平洋：子宮筋腫治療市場、最終用途別、2019～2032年
    • アジア太平洋：子宮筋腫治療薬市場、薬剤タイプ別、2019～2032年
    • 子宮筋腫治療市場- 中国
    • 子宮筋腫治療市場- インド
    • 子宮筋腫治療市場- マレーシア
    • 子宮筋腫治療市場- 日本
    • 子宮筋腫治療市場- インドネシア
    • 子宮筋腫治療市場- 韓国
  • 子宮筋腫治療市場-中東およびアフリカ
    • 中東およびアフリカ：子宮筋腫治療市場、薬剤クラス別、2019～2032年
    • 中東およびアフリカ：子宮筋腫治療市場、最終用途別、2019～2032年
    • 中東およびアフリカ：子宮筋腫治療市場、薬剤タイプ別、2019～2032年
    • 子宮筋腫治療市場- サウジアラビア
    • 子宮筋腫治療市場-UAE
    • 子宮筋腫治療市場- イスラエル
    • 子宮筋腫治療市場- 南アフリカ
  • 子宮筋腫治療市場-ラテンアメリカ
    • ラテンアメリカ：子宮筋腫治療市場、薬剤クラス別、2019-2032年
    • ラテンアメリカ：子宮筋腫治療市場、最終用途別、2019-2032
    • ラテンアメリカ：子宮筋腫治療市場、薬剤タイプ別、2019-2032年
    • 子宮筋腫治療市場- メキシコ
    • 子宮筋腫治療市場- ブラジル
    • 子宮筋腫治療市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Myovant Sciences
  • Pfizer
  • Abbvie
  • Ferring
  • AstraZeneca
  • Bayer
  • Amring Pharmaceuticals
  • Watson Pharma
図表

List of Tables

  • Table 1 Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 4 Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 20 France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 44 India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Uterine Fibroid Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Uterine Fibroid Treatment Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Uterine Fibroid Treatment Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Uterine Fibroid Treatment Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 12. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Uterine Fibroid Treatment Market
目次
Product Code: PM3549

The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report "Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

GnRH antagonists' segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.

Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women

Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies

North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.

The global players include: Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Gonadotropin-releasing Hormone (GnRH) Antagonists
  • Progestin-releasing Intrauterine Device (IUD) & Contraceptives
  • Non-hormonal Medications
  • Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data End Uses
    • 3.2.1. Primary End Uses
    • 3.2.2. Secondary End Uses

4. Global Uterine Fibroid Treatment Market Insights

  • 4.1. Uterine Fibroid Treatment Market - End Use Snapshot
  • 4.2. Uterine Fibroid Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Population Base For Uterine Fibroids Patients
      • 4.2.1.2. Growing Awareness Initiatives Related To Uterine Fibroids Diagnosis And Treatment
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent Regulatory Framework
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Uterine Fibroid Treatment Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Uterine Fibroid Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Gonadotropin-releasing Hormone (GnRH) Agonists
    • 5.3.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Agonists, by Region, 2019-2032 (USD Billion)
  • 5.4. Gonadotropin-releasing Hormone (GnRH) Antagonists
    • 5.4.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Antagonists, by Region, 2019-2032 (USD Billion)
  • 5.5. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
    • 5.5.1. Global Uterine Fibroid Treatment Market, by Progestin-releasing Intrauterine Device (IUD) & Contraceptives, by Region, 2019-2032 (USD Billion)
  • 5.6. Non-hormonal Medications
    • 5.6.1. Global Uterine Fibroid Treatment Market, by Non-hormonal Medications, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Uterine Fibroid Treatment Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Uterine Fibroid Treatment Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Subserosal Fibroids
    • 6.3.1. Global Uterine Fibroid Treatment Market, by Subserosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.4. Intramural Fibroids
    • 6.4.1. Global Uterine Fibroid Treatment Market, by Intramural Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.5. Submucosal Fibroids
    • 6.5.1. Global Uterine Fibroid Treatment Market, by Submucosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.6. Pedunculated Fibroids
    • 6.6.1. Global Uterine Fibroid Treatment Market, by Pedunculated Fibroids, by Region, 2019-2032 (USD Billion)

7. Global Uterine Fibroid Treatment Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Uterine Fibroid Treatment Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Uterine Fibroid Treatment Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Uterine Fibroid Treatment Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Uterine Fibroid Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Uterine Fibroid Treatment Market - North America
    • 8.3.1. North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Uterine Fibroid Treatment Market - U.S.
      • 8.3.4.1. U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Uterine Fibroid Treatment Market - Canada
      • 8.3.5.1. Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Uterine Fibroid Treatment Market - Europe
    • 8.4.1. Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Uterine Fibroid Treatment Market - UK
      • 8.4.4.1. UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Uterine Fibroid Treatment Market - France
      • 8.4.5.1. France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Uterine Fibroid Treatment Market - Germany
      • 8.4.6.1. Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Uterine Fibroid Treatment Market - Italy
      • 8.4.7.1. Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Uterine Fibroid Treatment Market - Spain
      • 8.4.8.1. Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Uterine Fibroid Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Uterine Fibroid Treatment Market - Russia
      • 8.4.10.1. Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Uterine Fibroid Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Uterine Fibroid Treatment Market - China
      • 8.5.4.1. China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Uterine Fibroid Treatment Market - India
      • 8.5.5.1. India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Uterine Fibroid Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Uterine Fibroid Treatment Market - Japan
      • 8.5.7.1. Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Uterine Fibroid Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Uterine Fibroid Treatment Market - South Korea
      • 8.5.9.1. South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Uterine Fibroid Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Uterine Fibroid Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Uterine Fibroid Treatment Market - UAE
      • 8.6.5.1. UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Uterine Fibroid Treatment Market - Israel
      • 8.6.6.1. Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Uterine Fibroid Treatment Market - South Africa
      • 8.6.7.1. South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Uterine Fibroid Treatment Market - Latin America
    • 8.7.1. Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Uterine Fibroid Treatment Market - Mexico
      • 8.7.4.1. Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Uterine Fibroid Treatment Market - Brazil
      • 8.7.5.1. Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Uterine Fibroid Treatment Market - Argentina
      • 8.7.6.1. Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Myovant Sciences
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Abbvie
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Ferring
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. AstraZeneca
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Bayer
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Amring Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Watson Pharma
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development